Product image of Maysiglu (Sitagliptin) supplied by GNH India

Maysiglu

Active Ingredient:
Sitagliptin
Origin:
EU

Maysiglu (Sitagliptin)

Sitagliptin, the active ingredient in Maysiglu, is a DPP-4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults when diet and exercise alone are insufficient.

GNH India supplies Maysiglu as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Krka, D.D., Novo Mesto

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Maysiglu (sitagliptin) is used within the antidiabetic therapeutic pathway to improve glycaemic control in patients with type 2 diabetes.

  • Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose as monotherapy or in combination with other agents.
  • Adjunct to diet and exercise: helps patients achieve target HbA1c levels when lifestyle measures are inadequate.
  • Combination therapy with metformin: provides additional glucose reduction for patients requiring dual oral therapy.

How It Works

  • Sitagliptin selectively inhibits the dipeptidyl peptidase‑4 (DPP‑4) enzyme, preventing the breakdown of endogenous incretin hormones such as GLP‑1 and GIP. Elevated incretin levels enhance glucose‑dependent insulin secretion from pancreatic beta cells and suppress glucagon release from alpha cells, resulting in improved post‑prandial and overall glycaemic control.

Side Effects

Sitagliptin is generally well tolerated, but adverse reactions can occur.

Common Side Effects

  • Nasopharyngitis: mild upper‑respiratory tract infection symptoms.
  • Headache: transient mild to moderate headache.
  • Upper respiratory tract infection: cough, sore throat.
  • Gastrointestinal upset: nausea, abdominal discomfort.
  • Dizziness: occasional light‑headedness.

Serious or Rare Side Effects

  • Pancreatitis: severe abdominal pain requiring immediate medical attention.
  • Severe hypersensitivity: rash, angioedema, or anaphylaxis.
  • Bullous pemphigoid: blistering skin disorder.
  • Hepatic injury: elevated liver enzymes or hepatitis.
  • Severe joint pain: arthralgia with swelling.

Precautions & Warnings

When prescribing sitagliptin, clinicians should consider patient‑specific factors and safety measures.

  • Renal impairment: assess kidney function and adjust dose if needed.
  • Hepatic impairment: use with caution in patients with liver disease.
  • History of pancreatitis: monitor closely for recurrent episodes.
  • Concomitant insulin or sulfonylureas: increased risk of hypoglycaemia; adjust co‑therapy accordingly.
  • Allergic reactions: discontinue if severe rash or anaphylaxis occurs.
  • Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Avoid Interactions

Sitagliptin may interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise sitagliptin plasma levels.
  • Strong CYP2C8 inhibitors (e.g., gemfibrozil): can increase exposure and risk of adverse effects.

Moderate Interactions (Monitor Closely)

  • Insulin or sulfonylureas: additive glucose‑lowering effect may cause hypoglycaemia.
  • Rifampin: enzyme induction may reduce sitagliptin effectiveness.
  • Diuretics: may affect glucose control and require monitoring.

Frequently Asked Questions

Maysiglu contains sitagliptin, a DPP‑4 inhibitor that is prescribed to improve blood‑sugar control in adults with type 2 diabetes mellitus, either alone or together with other oral antidiabetic agents.

Sitagliptin blocks the DPP‑4 enzyme, which normally degrades incretin hormones. By preserving incretins, it enhances insulin release after meals and reduces glucagon secretion, leading to lower blood glucose levels.

The appropriate dose of sitagliptin is determined by the prescribing healthcare professional based on the patient’s renal function, glycaemic targets and any concomitant medications. Patients should follow the prescriber’s instructions.

Safety of sitagliptin in pregnancy and lactation has not been fully established. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified clinician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with sulfonylureas, sitagliptin has a lower risk of causing hypoglycaemia because its glucose‑dependent mechanism requires elevated blood sugar to act. Unlike metformin, it does not affect gastrointestinal absorption, making it an alternative for patients intolerant to metformin.

Maysiglu tablets should be stored at ambient temperature, below 25 °C, in the original blister pack. Keep them away from moisture, heat and direct sunlight to maintain product stability.

Maysiglu is taken orally, usually once daily with or without food, as directed by the prescriber. The tablet should be swallowed whole with water and not crushed or chewed.

Serious adverse events include pancreatitis, severe hypersensitivity reactions such as anaphylaxis, and rare skin disorders like bullous pemphigoid. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, or swelling.

Maysiglu is contraindicated in patients with a known hypersensitivity to sitagliptin or any component of the formulation. Caution is advised for individuals with severe renal impairment, a history of pancreatitis, or those taking strong CYP3A4 or CYP2C8 inhibitors.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Sitagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT